MCID: NNL002
MIFTS: 50

Nonalcoholic Steatohepatitis

Categories: Rare diseases, Liver diseases

Aliases & Classifications for Nonalcoholic Steatohepatitis

MalaCards integrated aliases for Nonalcoholic Steatohepatitis:

Name: Nonalcoholic Steatohepatitis 53 73
Non-Alcoholic Fatty Liver Disease 53
Non-Alcoholic Steatohepatitis 53
Nash 53

Classifications:



External Ids:

UMLS 73 C3241937

Summaries for Nonalcoholic Steatohepatitis

NIH Rare Diseases : 53 Nonalcoholic steatohepatitis, or NASH, is a common, often “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Nonalcoholic Steatohepatitis, also known as non-alcoholic fatty liver disease, is related to hepatitis and lipodystrophy, familial partial, type 2. An important gene associated with Nonalcoholic Steatohepatitis is SQSTM1 (Sequestosome 1), and among its related pathways/superpathways are Common Cytokine Receptor Gamma-Chain Family Signaling Pathways and Folate Metabolism. The drugs Pioglitazone and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart, and related phenotypes are growth/size/body region and behavior/neurological

Related Diseases for Nonalcoholic Steatohepatitis

Diseases related to Nonalcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 hepatitis 30.8 F2 GPT SLC17A5 TNF
2 lipodystrophy, familial partial, type 2 30.7 INS LEP
3 hemosiderosis 30.5 GPT HFE
4 morbid obesity 30.5 ADIPOQ INS LEP
5 acanthosis nigricans 30.2 ADIPOQ INS LEP
6 apnea, obstructive sleep 30.0 ADIPOQ INS LEP TNF
7 sleep apnea 30.0 ADIPOQ INS LEP TNF
8 chronic kidney failure 30.0 ADIPOQ INS LEP
9 portal hypertension 30.0 F2 GPT TNF
10 hepatitis c 29.8 GPT HFE KRT18 TNF
11 hepatitis b 29.6 F2 GPT SLC17A5 TNF
12 diabetes mellitus, noninsulin-dependent 29.5 ADIPOQ GPT INS LEP SLC17A5 TNF
13 cryptogenic cirrhosis 29.3 F2 HFE KRT18
14 alcoholic hepatitis 29.1 F2 GPT KRT18 SLC17A5 TNF
15 alcoholic liver cirrhosis 29.0 F2 PNPLA3 SLC17A5
16 liver cirrhosis 28.8 F2 GPT HFE SLC17A5
17 diabetes mellitus 28.7 ADIPOQ HFE INS LEP TNF
18 fatty liver disease 27.8 ADIPOQ GPT HFE INS KRT18 LEP
19 viral hepatitis 27.4 F2 GPT HFE KRT18 SLC17A5 TNF
20 liver disease 25.4 ADIPOQ F2 GPT HFE INS KRT18
21 nonalcoholic fatty liver disease 11.7
22 paraquat poisoning 10.7 GPT SLC17A5
23 burns 10.7 INS TNF
24 adult dermatomyositis 10.6 GPT TNF
25 pyridoxine deficiency 10.6 GPT SLC17A5
26 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.6 ADIPOQ INS
27 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.6 INS LEP
28 chronic pulmonary heart disease 10.6 ADIPOQ TNF
29 hepatocellular carcinoma 10.6
30 acquired generalized lipodystrophy 10.6 ADIPOQ LEP
31 idiopathic edema 10.6 ADIPOQ INS
32 obesity-hypoventilation syndrome 10.5 ADIPOQ LEP
33 fascioliasis 10.5 GPT SLC17A5
34 idiopathic recurrent pericarditis 10.5 ADIPOQ LEP
35 malignant otitis externa 10.5 F2 INS
36 multidrug-resistant tuberculosis 10.5 SLC17A5 TNF
37 hepatoportal sclerosis 10.5 F2 GPT
38 fetal macrosomia 10.4 INS LEP
39 marburg hemorrhagic fever 10.4 F2 TNF
40 mycobacterium abscessus 10.4 SQSTM1 TNF
41 choline deficiency disease 10.4
42 endometritis 10.4 SLC17A5 TNF
43 hepatic tuberculosis 10.4 F2 GPT
44 hepatic coma 10.4 F2 GPT
45 hepatitis d 10.4 F2 GPT
46 congenital generalized lipodystrophy 10.4 INS LEP
47 aging 10.3
48 scrub typhus 10.3 GPT SLC17A5 TNF
49 atherosclerosis susceptibility 10.3 ADIPOQ INS TNF
50 abdominal obesity-metabolic syndrome 1 10.3 ADIPOQ INS LEP

Graphical network of the top 20 diseases related to Nonalcoholic Steatohepatitis:



Diseases related to Nonalcoholic Steatohepatitis

Symptoms & Phenotypes for Nonalcoholic Steatohepatitis

MGI Mouse Phenotypes related to Nonalcoholic Steatohepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.06 TNF HFE SQSTM1 INS ADIPOQ KRT18
2 behavior/neurological MP:0005386 10.03 TNF SLC17A5 HFE SQSTM1 INS ADIPOQ
3 homeostasis/metabolism MP:0005376 9.97 TNF HFE SQSTM1 INS ADIPOQ LEP
4 hematopoietic system MP:0005397 9.91 SQSTM1 TNF HFE INS ADIPOQ LEP
5 adipose tissue MP:0005375 9.85 TNF SQSTM1 INS ADIPOQ LEP
6 integument MP:0010771 9.73 SQSTM1 TNF INS ADIPOQ LEP F2
7 liver/biliary system MP:0005370 9.7 TNF SQSTM1 INS ADIPOQ KRT18 LEP
8 mortality/aging MP:0010768 9.61 TNF SLC17A5 HFE SQSTM1 INS ADIPOQ
9 skeleton MP:0005390 9.17 TNF SQSTM1 INS ADIPOQ LEP F2

Drugs & Therapeutics for Nonalcoholic Steatohepatitis

Drugs for Nonalcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
4
Ribavirin Approved Phase 4,Not Applicable 36791-04-5 37542
5
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
6
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
7
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
8
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
9
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
10
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
11
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
12
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
13
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
14
Rifaximin Approved, Investigational Phase 4,Not Applicable 80621-81-4 6436173
15
Empagliflozin Approved Phase 4 864070-44-0
16
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
17
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
18
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-02-9 14985
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
20 insulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 interferons Phase 4,Not Applicable
22 diuretics Phase 4,Phase 2
23 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
24 Natriuretic Agents Phase 4,Phase 2
25 Sodium Chloride Symporter Inhibitors Phase 4
26 Tocopherols Phase 4,Phase 3,Phase 2,Not Applicable
27 Tocotrienols Phase 4,Phase 3,Phase 2,Not Applicable
28 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Trace Elements Phase 4,Phase 3,Phase 2,Not Applicable
30 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
32 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
33 Angiotensinogen Phase 4,Phase 3,Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
38 Antihypertensive Agents Phase 4,Phase 3,Phase 2
39 Anticholesteremic Agents Phase 4,Phase 2,Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Interferon-alpha Phase 4,Not Applicable
42 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antioxidants Phase 4,Phase 3,Phase 2,Not Applicable
44 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 rifamycin SV Phase 4,Not Applicable
50 Rifamycins Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 322)
# Name Status NCT ID Phase Drugs
1 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
3 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
6 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
7 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
8 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
9 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
10 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
11 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
12 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
13 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
14 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Enrolling by invitation NCT02210715 Phase 4 Isentress.
15 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Not yet recruiting NCT03198572 Phase 4 Placebo;Berberine
16 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
17 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
18 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
19 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
20 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
21 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
22 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
23 Metformin in Non-Alcoholic Fatty Liver Disease Unknown status NCT00303537 Phase 2, Phase 3 metformin
24 The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
25 Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis Completed NCT00820651 Phase 3
26 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
27 Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis Completed NCT00509418 Phase 3
28 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
29 Anti-Fibrotic Effects of Losartan In Nash Evaluation Study Completed NCT01051219 Phase 3 Losartan
30 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
31 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
32 Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
33 The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
34 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed NCT02279524 Phase 2, Phase 3 Aramchol
35 The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
36 Omega 3 Supplementation in Fatty Liver Completed NCT01992809 Phase 3
37 Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
38 Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
39 DHA and Vitamin D in Children With Biopsy-proven NAFLD Completed NCT02098317 Phase 3 DHA plus Vitamin D;Placebo
40 Role of Exenatide in NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
41 Development of a Breath Test for Monitoring Patients With Liver Disease Completed NCT00244569 Phase 3 13C-Methacetin
42 Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity Completed NCT00553852 Phase 3 Recombinant GH Saizen (Merck-Serono)
43 Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT00655018 Phase 2, Phase 3
44 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT02704403 Phase 3 Elafibranor;Placebo
45 Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis Recruiting NCT02541045 Phase 3 metadoxine
46 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
47 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Recruiting NCT03439254 Phase 3 Obeticholic acid (10 mg);Obeticholic acid (10 mg to 25 mg);Placebo
48 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Recruiting NCT02654665 Phase 3 Liraglutide
49 AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH Recruiting NCT03028740 Phase 3 Cenicriviroc;Placebo
50 Hydroxytyrosol and Vitamin E in Pediatric NASH Recruiting NCT02842567 Phase 3 Hydroxytyrosol plus Vitamin E;Placebo

Search NIH Clinical Center for Nonalcoholic Steatohepatitis

Genetic Tests for Nonalcoholic Steatohepatitis

Anatomical Context for Nonalcoholic Steatohepatitis

MalaCards organs/tissues related to Nonalcoholic Steatohepatitis:

41
Liver, Testes, Heart, Kidney, Bone, Endothelial, Spleen

Publications for Nonalcoholic Steatohepatitis

Articles related to Nonalcoholic Steatohepatitis:

(show top 50) (show all 843)
# Title Authors Year
1
Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. ( 29381754 )
2018
2
Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe? ( 29930864 )
2018
3
Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models. ( 29800811 )
2018
4
Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis. ( 29942224 )
2018
5
Metabolic Syndrome is Associated with Health-Related Quality of Life in Suspected Patients with Nonalcoholic Steatohepatitis. ( 29402822 )
2018
6
Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis. ( 29870802 )
2018
7
Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. ( 29913275 )
2018
8
Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water. ( 29959418 )
2018
9
Haptoglobin Genotype and VitaminA E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. ( 29411270 )
2018
10
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. ( 29291351 )
2018
11
Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis. ( 29930468 )
2018
12
Nonalcoholic steatohepatitis: the new frontier for liver transplantation. ( 29356708 )
2018
13
Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis. ( 29912756 )
2018
14
Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis. ( 29797529 )
2018
15
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. ( 29802399 )
2018
16
Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. ( 29761169 )
2018
17
Risk factors and clinical course for liver steatosis or nonalcoholic steatohepatitis after living donor liver transplantation. ( 29894414 )
2018
18
Organic Solute Transporter OSTI+/A9 is Over-Expressed in Nonalcoholic Steatohepatitis and Modulated by Drugs Associated with Liver Injury. ( 29420067 )
2018
19
Dual regulation of HMGB1 by combined JNK1/2-ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice. ( 29298863 )
2018
20
A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. ( 29311502 )
2018
21
Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis. ( 29555473 )
2018
22
Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. ( 29341352 )
2018
23
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. ( 29406435 )
2018
24
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. ( 29375204 )
2018
25
Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. ( 29401710 )
2018
26
Relationship between intestinal flora and inflammatory factors in patients with nonalcoholic steatohepatitis. ( 29399077 )
2018
27
A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 29769552 )
2018
28
Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. ( 29404772 )
2018
29
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. ( 29367468 )
2018
30
Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. ( 29299759 )
2018
31
The accuracy of noninvasive scoring systems for diagnosing nonalcoholic steatohepatitis-related fibrosis: multi-center validation study. ( 29974624 )
2018
32
Inflammasome activation in Kupffer cells confers a protective response in nonalcoholic steatohepatitis through pigment epithelium-derived factor expression. ( 29897812 )
2018
33
IL6R Gene Polymorphic Variant rs2228145(C >A) as a Marker of Genetic Liability to Nonalcoholic Steatohepatitis in the Russian Population of Karelia. ( 29797122 )
2018
34
Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis. ( 29912761 )
2018
35
Mouse Models Of Nonalcoholic Steatohepatitis: A Reflection On Recent Literature. ( 29424123 )
2018
36
Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage. ( 29881817 )
2018
37
Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis. ( 29128353 )
2018
38
Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes. ( 29978150 )
2018
39
Alisol A 24-acetate ameliorates nonalcoholic steatohepatitis by inhibiting oxidative stress and stimulating autophagy through the AMPK/mTOR pathway. ( 29883724 )
2018
40
Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. ( 28079667 )
2017
41
Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. ( 28936971 )
2017
42
Global Deletion of Glutathione S-Transferase A4 Exacerbates Developmental Nonalcoholic Steatohepatitis. ( 27998724 )
2017
43
Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. ( 28941597 )
2017
44
The association of nonalcoholic steatohepatitis and obstructive sleep apnea. ( 28914694 )
2017
45
Nonalcoholic steatohepatitis in children with severe obesity: A global concern. ( 28935179 )
2017
46
p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress. ( 28286271 )
2017
47
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. ( 28912902 )
2017
48
Hepatic vagus nerve regulates Kupffer cell activation via I+7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis. ( 28044208 )
2017
49
Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. ( 28218919 )
2017
50
The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. ( 27922486 )
2017

Variations for Nonalcoholic Steatohepatitis

Expression for Nonalcoholic Steatohepatitis

Search GEO for disease gene expression data for Nonalcoholic Steatohepatitis.

Pathways for Nonalcoholic Steatohepatitis

GO Terms for Nonalcoholic Steatohepatitis

Cellular components related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 ADIPOQ F2 GPT HFE INS LEP

Biological processes related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.94 INS KRT18 LEP SQSTM1
2 positive regulation of protein kinase B signaling GO:0051897 9.77 INS LEP TNF
3 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.65 SQSTM1 TNF
4 glucose homeostasis GO:0042593 9.65 ADIPOQ INS LEP
5 regulation of signaling receptor activity GO:0010469 9.65 ADIPOQ F2 INS LEP TNF
6 positive regulation of glucose import GO:0046326 9.64 ADIPOQ INS
7 positive regulation of cytokine production GO:0001819 9.63 LEP TNF
8 positive regulation of reactive oxygen species metabolic process GO:2000379 9.63 F2 LEP
9 positive regulation of cytokine secretion GO:0050715 9.62 INS TNF
10 positive regulation of interleukin-8 production GO:0032757 9.62 ADIPOQ TNF
11 negative regulation of proteolysis GO:0045861 9.61 F2 INS
12 positive regulation of protein localization to nucleus GO:1900182 9.61 F2 INS
13 positive regulation of JAK-STAT cascade GO:0046427 9.6 F2 LEP
14 positive regulation of long-term synaptic potentiation GO:1900273 9.58 INS SQSTM1
15 negative regulation of lipid catabolic process GO:0050995 9.58 INS TNF
16 leukocyte tethering or rolling GO:0050901 9.57 LEP TNF
17 regulation of protein secretion GO:0050708 9.56 INS TNF
18 positive regulation of cellular protein metabolic process GO:0032270 9.55 ADIPOQ INS
19 positive regulation of insulin receptor signaling pathway GO:0046628 9.54 INS LEP
20 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.54 F2 INS LEP
21 negative regulation of growth of symbiont in host GO:0044130 9.52 SQSTM1 TNF
22 negative regulation of gluconeogenesis GO:0045721 9.51 ADIPOQ INS
23 response to nutrient levels GO:0031667 9.5 ADIPOQ INS LEP
24 negative regulation of glucose import GO:0046325 9.49 LEP TNF
25 negative regulation of lipid storage GO:0010888 9.46 LEP TNF
26 positive regulation of protein phosphorylation GO:0001934 9.46 ADIPOQ F2 SQSTM1 TNF
27 positive regulation of peptide hormone secretion GO:0090277 9.43 HFE INS
28 negative regulation of receptor binding GO:1900121 9.4 ADIPOQ HFE
29 acute-phase response GO:0006953 9.13 F2 HFE INS
30 glucose metabolic process GO:0006006 8.92 ADIPOQ INS LEP TNF

Molecular functions related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.26 ADIPOQ F2 HFE LEP
2 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Nonalcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....